Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Andreas Hochhaus, ASH 2020 – The ASCEMBL Study and Asciminib in CML

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 3rd 2021

touchONCOLOGY meets with Prof. Andreas Hochhaus to discuss the clinical development of asciminib and its potential as a therapy for chronic myeloid leukaemia. The abstract ‘Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs)’ (LBA-4) was presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Questions

  1. What are the limitations of tyrosine kinase inhibitor therapy in patients with chronic myeloid leukaemia? (0:17)
  2. Could you tell us a little about asciminib and its mechanism of action? (2:45)
  3. What were the aims and design of the ASCEMBL study? (5:37)
  4. What were the efficacy and safety findings of the ASCEMBL study? (7:15)
  5. What will be the next steps in the clinical development of asciminib? (8:52)

 

Speaker Disclosures: Prof. Andreas Hochhaus  has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup